Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.
What Solara files
- Others84
- Updates28
- Investor Meet24
- Important19
- Board Meeting16
- Credit Ratings2
Solara divested a subsidiary, a strategic portfolio adjustment. The company reported zero fines and achieved an 8.5% reduction in Scope 1 & 2 GHG emissions. Zero Liquid Discharge is implemented at 5 of 6 sites. However, worker safety incidents saw an uptick.
Solara Active Pharma Sciences appointed Ajit Manocha as Chief Information Officer. He brings 33 years of global experience in digital transformation, SAP, Industry 4.0, IoT, AI, and cybersecurity, aiming to enhance technology strategy in life sciences.
Solara reported strong Q1’27 with base business revenue up 24% YoY to ₹30.77 Cr and EBITDA up 8% to ₹7.22 Cr. Overall, highest EBITDA (₹6.35 Cr) and PAT (₹1.63 Cr) in 18 quarters. Debt reduced by ₹13.46 Cr to ₹47.95 Cr. Strategic options for challenging Ibuprofen business are under evaluation.
Solara Pharma issued a final reminder for partly paid shares. Pay ₹131.25 (First Call) and/or ₹112.50 (Second & Final Call) to avoid forfeiture. Successful payment converts your shares to ₹10 fully paid equity. Act now to secure your investment.
Solara Active Pharma Sciences is transferring shares with unclaimed dividends (FY 2018-19 onwards) to the IEPF. Affected shareholders, whose dividends remained unpaid for 7 years, can reclaim these shares and future benefits directly from the IEPF.